KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Long-Term Investments: 2019-2024

Historic Long-Term Investments for Adaptive Biotechnologies (ADPT) over the last 4 years, with Dec 2024 value amounting to $33.7 million.

  • Adaptive Biotechnologies' Long-Term Investments fell 83.08% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 83.08%. This contributed to the annual value of $33.7 million for FY2024, which is N/A change from last year.
  • Per Adaptive Biotechnologies' latest filing, its Long-Term Investments stood at $33.7 million for FY2024, which was down 84.50% from $217.1 million recorded in FY2021.
  • In the past 5 years, Adaptive Biotechnologies' Long-Term Investments ranged from a high of $217.1 million in FY2021 and a low of $33.7 million during FY2024.
  • In the last 1 years, Adaptive Biotechnologies' Long-Term Investments had a median value of $33.7 million in 2024 and averaged $33.7 million.
  • Data for Adaptive Biotechnologies' Long-Term Investments shows a peak YoY soared of 83.21% (in 2021) over the last 5 years.
  • Over the past 3 years, Adaptive Biotechnologies' Long-Term Investments (Yearly) stood at $118.5 million in 2020, then soared by 83.21% to $217.1 million in 2021, then reached $33.7 million in 2024.